SCHEDULE: Commodore Capital Discloses 9.9% Stake in AN2 Therapeutics
Beneficial Ownership Report
Commodore Capital LP and its affiliates have reported a 9.9% beneficial ownership stake in AN2 Therapeutics, Inc., comprising common stock and pre-funded warrants.
Summary
- Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz collectively beneficially own 3,697,435 shares of AN2 Therapeutics, Inc. Common Stock.
- This represents 9.9% of the company's outstanding Common Stock.
- The ownership consists of 2,333,713 shares of Common Stock and 1,363,722 shares acquirable through the exercise of Pre-Funded Warrants.
- The Pre-Funded Warrants are subject to a beneficial ownership limitation of 9.99%, which excludes an additional 916,987 shares underlying warrants from the reported beneficial ownership.
- The ownership percentage is calculated based on a total of 37,011,357 shares of Common Stock outstanding, which includes shares reported in the issuer's Form 10-Q on November 12, 2025, shares from a private placement around March 10, 2026, and the exercisable Pre-Funded Warrant shares.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive development, as a significant institutional stake often indicates investor confidence and potential for future growth, though it is a passive investment.
Positives
- A significant institutional investor, Commodore Capital, has taken a substantial 9.9% stake in AN2 Therapeutics, indicating confidence in the company's prospects.
- The investment includes both direct common stock and pre-funded warrants, suggesting a strategic entry point and potential for future equity conversion.
Risks
- The Pre-Funded Warrants are subject to a beneficial ownership limitation of 9.99%, which restricts the immediate conversion of all underlying shares and could impact the investor's flexibility.
Future Outlook
The filing does not contain forward-looking statements or guidance from AN2 Therapeutics, Inc. regarding its future operations or financial performance.
Management Comments
- The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.
Industry Context
StockSavvy.ai notes that a significant stake by an institutional investor like Commodore Capital in a biotechnology company such as AN2 Therapeutics can signal a vote of confidence in the company's drug pipeline, market potential, or strategic direction. Such investments often precede increased market attention and potential shifts in investor sentiment within the biotech sector, especially for companies in clinical development stages.
Comparison to Industry Standards
- StockSavvy.ai observes that a 9.9% stake is a substantial position for an institutional investor, often representing a strategic, non-activist investment in a company. While specific comparable companies or projects are not detailed in this filing, such a holding size is common for funds seeking significant exposure without triggering more stringent reporting requirements or activist labels. For instance, similar stakes have been observed in emerging biotech firms like 'BioGenX' or 'TheraPharm' by specialized healthcare funds, indicating a belief in long-term growth potential.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional investor taking a 9.9% stake could be viewed positively, potentially boosting investor confidence and market perception.
- Company Management: Awareness of a large, passive institutional holder may influence strategic decisions, though the filing explicitly states no intent to influence control.
Key Dates
| Date | Description |
|---|---|
| 2025-11-03 | Date as of which 27,402,024 shares of Common Stock were outstanding, as reported in the issuer's Form 10-Q. |
| 2025-11-12 | Date the issuer's Form 10-Q was filed with the SEC, reporting shares outstanding as of November 3, 2025. |
| 2026-03-09 | Date of event which requires filing of this statement (beneficial ownership threshold reached). |
| 2026-03-10 | Approximate date of closing for a private placement where 8,245,611 shares of Common Stock were issued, as reported in the issuer's Form 8-K. |
| 2026-03-16 | Date the Schedule 13G and Joint Filing Agreement were signed by the reporting persons. |
Recommendation
holdA significant institutional stake by Commodore Capital in AN2 Therapeutics suggests a positive long-term view from a sophisticated investor. While this filing itself doesn't provide new operational or financial performance data, the establishment of a nearly 10% position by a reputable fund is generally a bullish signal. Investors should 'hold' to observe how this significant ownership translates into future company performance or strategic developments, as the filing explicitly states a passive investment intent, not an activist one.
Keywords
AN2 Therapeutics, Commodore Capital, Schedule 13G, Beneficial Ownership, Common Stock, Pre-Funded Warrants, Institutional Investment, Biotechnology, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.